The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Jul. 23, 4:07 PM

Slide #16. Ironwood Pharmaceuticals Secondary Offering

Company: Ironwood Pharmaceuticals (NASDAQ:IRWD)
Date announced: 2/10/2014
Shares Offered: 13,725,500
Date of Pricing: 2/11/2014
Price Per Share: $12.75
Secondary Offering Details: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that it has commenced a $150 million underwritten public offering of its Class A common stock. All of the shares are being offered by Ironwood. Ironwood will grant the underwriters a 30-day option to purchase additional shares equal to up to 15% of the number of shares of Class A common stock sold in the offering. - updated 2/12 -Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the pricing of an underwritten public offering of 13,725,500 shares of its Class A common stock at a price of $12.75 per share to the public. All of the shares are being offered by Ironwood. The gross proceeds to Ironwood from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Ironwood. The offering is expected to close on February 14, 2014, subject to the satisfaction of customary closing conditions.

Ironwood Pharmaceuticals is a pharmaceutical company engaged in the discovery, development and commercialization of medicines. Co.'s primary product, linaclotide, is being marketed in the U.S. under the trademarked name of LINZESS™, as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation. LINZESS has also been approved in the European Union under the trademarked name Constella. Co. also has a pipeline of early development candidates and discovery research in multiple therapeutic areas, including gastrointestinal disease, central nervous system disorders, allergic conditions and cardiovascular disease.
Open the IRWD Page at The Online Investor »

Company Name:  Ironwood Pharmaceuticals Inc.
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding IRWD:  21
Total Market Value Held by ETFs:  $90.32M
Total Market Capitalization:  $1.75B
% of Market Cap. Held by ETFs:  5.17%

Open the IRWD Page at The Online Investor (in a new window) »

July 23, 2014    4:07 PM Eastern
Quotes delayed 20 minutes

Buy (2.80 out of 4)
33rd percentile
(ranked lower than approx. 67% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.